LeonaBio annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
LeonaBio Stock-Based Compensation Growth & History (LONA)
LeonaBio's stock-based compensation was $6.1M for fiscal 2025.
View full LeonaBio company overviewLeonaBio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.1M | −$4.9M | −44.77% |
| 2024 | 2024-12-31 | $11.0M | $426,000 | +4.01% |
| 2023 | 2023-12-31 | $10.6M | $17,000 | +0.16% |
| 2022 | 2022-12-31 | $10.6M | $6.0M | +129.42% |
| 2021 | 2021-12-31 | $4.6M | $4.0M | +630.33% |
| 2020 | 2020-12-31 | $633,000 | $380,000 | +150.20% |
| 2019 | 2019-12-31 | $253,000 | — | — |
LeonaBio quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.2M | $1.6M | +99.19% |
| Q1 2026 | 2026-03-31 | $662,000 | −$975,000 | −59.56% |
| Q4 2025 | 2025-12-31 | $1.5M | −$771,000 | −34.59% |
| Q3 2025 | 2025-09-30 | $1.4M | −$1.5M | −51.98% |
| Q2 2025 | 2025-06-30 | $1.6M | −$1.6M | −50.17% |
| Q1 2025 | 2025-03-31 | $1.6M | −$1.0M | −38.90% |
| Q4 2024 | 2024-12-31 | $2.2M | $1,000 | +0.04% |
| Q3 2024 | 2024-09-30 | $2.9M | $442,000 | +17.72% |
| Q2 2024 | 2024-06-30 | $3.2M | $86,000 | +2.76% |
| Q1 2024 | 2024-03-31 | $2.7M | −$103,000 | −3.70% |
| Q4 2023 | 2023-12-31 | $2.2M | −$132,000 | −5.59% |
| Q3 2023 | 2023-09-30 | $2.5M | $74,000 | +3.06% |
| Q2 2023 | 2023-06-30 | $3.1M | $24,000 | +0.78% |
| Q1 2023 | 2023-03-31 | $2.8M | $51,000 | +1.87% |
| Q4 2022 | 2022-12-31 | $2.4M | $925,000 | +64.46% |
| Q3 2022 | 2022-09-30 | $2.4M | $1.3M | +119.00% |
| Q2 2022 | 2022-06-30 | $3.1M | $2.0M | +179.08% |
| Q1 2022 | 2022-03-31 | $2.7M | $1.8M | +180.39% |
| Q4 2021 | 2021-12-31 | $1.4M | $1.0M | +245.78% |
| Q3 2021 | 2021-09-30 | $1.1M | $994,000 | +895.50% |
| Q2 2021 | 2021-06-30 | $1.1M | $1.1M | +2163.27% |
| Q1 2021 | 2021-03-31 | $974,000 | $916,000 | +1579.31% |
| Q4 2020 | 2020-12-31 | $415,000 | — | — |
| Q3 2020 | 2020-09-30 | $111,000 | $42,000 | +60.87% |
| Q2 2020 | 2020-06-30 | $49,000 | — | — |
| Q1 2020 | 2020-03-31 | $58,000 | — | — |
| Q3 2019 | 2019-09-30 | $69,000 | — | — |
LeonaBio stock-based compensation trends
Over the last five fiscal years, LeonaBio's stock-based compensation increased from $633,000 to $6.1M, a change of $5.5M. The latest reported quarter, Q2 2026, shows $3.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review LeonaBio source filings ↗